INOVIQ LTD — Capital/Financing Update 2017

Jul 4, 2017

==> picture [155 x 50] intentionally omitted <==

CAPITAL RAISING

Perth, Australia, 05 July 2017: Australian biotechnology company BARD1 Life Sciences Limited (ASX:BD1) ( BARD1 LSL or the Company ) is pleased to announce that it has received binding commitments for a share placement to raise $1,097,325 (before costs) by the issue of 137,165,811 new shares to sophisticated and professional investors at an issue price of $0.008 cents per share ( Placement ).

The Placement, will be made under the Company’s existing placement capacities available under ASX Listing Rules 7.1 and 7.1A. It is anticipated that settlement of the Placement will occur on Monday, 10 July 2017 with the new shares to be issued shortly after. CPS Securities Limited is acting as Lead Manager to the Placement.

The Company will also conduct a Share Purchase Plan for eligible shareholders to raise up to a further $1 million ( SPP ).

The SPP will enable existing eligible shareholders to participate in the capital raising by applying for up to $15,000 worth of shares at the same issue price as the Placement and without incurring any brokerage fees or other transaction costs. The issue price of $0.008 per share represents a 19.1% discount to the 5 day VWAP of $0.009894 per share up to 30 June 2017, being the last trading day prior to the Company’s announcement of the SPP. If an eligible shareholder holds shares as a ‘custodian’ (as that term is defined in ASIC Class Order ([CO 09/425]), the offer under the SPP will be made to the ‘custodian’ and, subject to a number of conditions, the ‘custodian’ will have the discretion to extend the offer to the relevant beneficiaries. An offer document in relation to the SPP will be uploaded to ASX and sent to shareholders shortly.

All new shares issued under the Placement and SPP will rank equally in all respects with the existing fully paid ordinary shares of the Company.

Funds raised from the Placement and SPP will be used to fund ongoing research and development programs, commercial initiatives and for general working capital purposes.

• ENDS -

FOR MORE INFORMATION PLEASE CONTACT:

Peter Gunzburg	Dr Leearne Hinch
Chairman	CEO
E peter@bard1.com	E leearne@bard1.com
	M+61 400 414 416

BARD1 Life Sciences Limited (ABN 58 009 070 384) Headquarters | Harry Perkins Institute, L2/QQ Block, 6 Verdun St, Nedlands WA 6009, Australia Registered Office | Suite B1, Tempo Building, 431 Roberts Road, Subiaco WA 6008, Australia P +618 9381 9550 | F +618 9388 7559 | E info@bard1.com | W www.bard1.com